Charleston, SC (August 27, 2013) – The Medical University of South Carolina (MUSC) this morning hosted “Research in Your Backyard,” a press conference announcing the key findings of a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) that focuses on clinical trials being conducted by biopharmaceutical research companies and local research collaborators throughout South Carolina. Rep. James Clyburn was a featured speaker at the conference, which took place inside the Drug Discovery Building of the James E. Clyburn Research Center.
The report emphasizes that biopharmaceutical companies are a vital component to South Carolina’s economy and remain critical to patient health in the state. From 1999 to present, South Carolina’s biopharmaceutical companies are conducting or have conducted more than 3,200 clinical trials of new medicines in collaboration with the state’s clinical research centers, university medical schools and hospitals, including the Medical University of South Carolina.
“Research in Your Backyard” speakers included:
- Rep. James Clyburn (D/SC-06)
- Chester “Chip” Davis, executive vice president, PhRMA
- Dr. Stephen Lanier, Associate Provost for Research, MUSC
- Andrew S. Kraft, M.D., Director, Hollings Cancer Center
- Kathleen Brady, M.D., Ph.D., Director, South Carolina Clinical and Translational Research Institute (SCTR); Clinical Translational Science Award Principal Investigator
- Marvella E. Ford, PhD, Professor of Public Health Sciences, Hollings Cancer Center
- Wayne Roper, president, SCBIO
“Ending health disparities has been a priority of my service in Congress, and I am committed to any effort that helps to reduce those disparities,” said Rep. Clyburn. “Today’s report will hopefully raise awareness about the value of participating in clinical trials so more patients across South Carolina may share in the benefits and the hope these trials can provide.”
Of the aforementioned clinical trials, nearly 1,700 have targeted the nation’s six most debilitating chronic diseases: asthma, cancer, diabetes, heart disease, mental illnesses, and stroke. Nearly 300 clinical trials focusing on these six diseases are still actively recruiting patients, and all are helping to advance cutting-edge science and patient care in South Carolina.
“Clinical trials provide an important message of hope for patients who seek new treatment for unmet medical needs. These trials advance medical knowledge, lead to better patient care and drive economic growth across South Carolina,” said Chip Davis, executive vice president, PhRMA. “Clinical trials are also a powerful example of strong public-private partnerships that are good for the state and good for public health. America’s biopharmaceutical companies are proud of the work we’re doing in South Carolina, and we look forward to continued work on behalf of patients across the state.”
The economic impact of South Carolina’s biopharmaceutical industry is equally profound: the biopharmaceutical industry supported more than 18,000 jobs in South Carolina, and directly generated $2.4 billion in economic output in the state and supported another $1.8 billion in products and services through its vendors and suppliers. The 4,800 employees working directly for the biopharmaceutical sector alone accounted for $352 million in pay and benefits, resulting in more than $56 million in tax money for the federal and state governments.
What is more, South Carolinians contemplating participation in clinical trials have a wide range of choices throughout the state, with trials focused on various conditions available in the following 13 cities: Anderson, Charleston, Columbia, Easley, Greenville, Greer, Hilton Head, Mt. Pleasant, Myrtle Beach, Orangeburg, Spartanburg, Summerville and Sumter.
For more information on clinical trials in South Carolina, please visit PhRMA.org and www.clinicaltrials.gov, the clinical trial data base of the National Institutes of Health.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.
Find PhRMA Online: